Listing 3 - Actual negotiations

Indication:

In combination with lenalidomide for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, who are not eligible for autologous stem cell transplant (ASCT).

Indication:

Primary biliary cholangitis

Indication:

As monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma (Grades 1 – 3a) who have received at least two prior lines of systemic therapy.

Indication:

As monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma (Grades 1 – 3a) who have received at least two prior lines of systemic therapy.

Indication:

An add-on to standard therapy for the treatment of Generalized myasthenia gravis (gMG) in adult and adolescent patients aged 12 years and older who are anti-AChR or anti-MuSK antibody positive.

Indication:

For the treatment of multiple myeloma in combination with bortezomib and dexamethasone (BVd) in adult patients who have received at least one prior therapy.

Indication:

For the treatment of multiple myeloma in combination with pomalidomide and dexamethasone (Bpd) in adult patients who have received at least one prior therapy including lenalidomide.

Indication:

Keytruda (pembrolizumab), for the treatment of adult patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin containing chemotherapy, in combination with enfortumab vedotin (Padcev), as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment.

Indication:

Active lupus nephritis

Indication:

As an adjunct to standard of care in adults with heart failure with left ventricular ejection fraction (LVEF) ≥ 40% to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits.